Share on StockTwits

bluebird bio (NASDAQ:BLUE) COO Jeffrey T. Walsh sold 1,500 shares of the company’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $20.03, for a total value of $30,045.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of bluebird bio (NASDAQ:BLUE) opened at 24.52 on Friday. bluebird bio has a 1-year low of $17.03 and a 1-year high of $36.25. The stock has a 50-day moving average of $20.71 and a 200-day moving average of $21.8. The company’s market cap is $592.6 million.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. Analysts expect that bluebird bio will post $-1.39 EPS for the current fiscal year.

A number of analysts have recently weighed in on BLUE shares. Analysts at Zacks upgraded shares of bluebird bio from an “underperform” rating to a “neutral” rating in a research note on Wednesday. They now have a $19.90 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $37.73.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.